|
Symposium
[In-Person] Advances in Cancer Therapeutics
Speakers:
Alex Cacovean (Biomea Fusion), Eric Blouin, (Ipsos), Umer Raffat (Evercore), Amar Patel (BMS), Kelsey Gauthier (Arcus), Allison Roberts (Frontier Medicines), Jennifer Low (23andMe), Shiva Bhowmik (Trio Pharmaceuticals), Dirk Brockstedt (RAPT Therapeutics), Dara L. Burdette (Tempest Therapeutics), Cheng Liu (Eureka Therapeutics)
Organizers:
Toby Freedman (Synapsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)
Date:
2023-09-21
Time:
8:45-18:30 Pacific Time
Registration fee:
Regular attendees: $195; Academic/Students/Postdocs/Between Jobs: $95; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $995; Lunch Sponsorship: $1250; On-site Registration:$500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(13)Aragen; ATUM; Biocytogen Boston Corp; Correlia Biosystems Inc; Curis Decontamination Systems; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Inotiv; Meadowhawk Biolabs; PharmaBlock; Revvity; SOLVO/CRL
Registration: http://www.PBSS.org
Registration deadline:2023-09-19
(it will close sooner if the seating cap is reached)
About the Topic
This one-day symposium will discuss the latest advances in the discovery and development of cancer therapeutics from leading pharmaceutical companies and promising biotech companies.
Presenting Companies / Speakers:
- Bristol Myers Squibb-Amar Patel, MD, Senior Director, Early Clinical Development: Advancing Novel Modalities for the Treatment of Hematologic Cancers
- Arcus-Kelsey Gauthier, PhD, Director of Biology: Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells.
- Biomea Fusion-Alex Cacovean, MD, VP, Clinical Development: First-in-Class Covalent MENIN Inhibitors for AML.
- Evercore ISI-Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director: ASCO Highlights.
- Ipsos Healthcare-Eric Blouin, SVP of Oncology: New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
- Frontier Medicines-Allison Roberts, PhD, Senior Scientist,Chemical Biology: Challenging Cancer with Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor.
- 23andMe-Jennifer Low, MD, PhD, Head of Therapeutics Development: Developing genetically-validated drugs using 23andMe's genetic database.
- Trio Pharmaceuticals-Shiva Bhowmik, PhD, founder nad COO: Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity.
- RAPT Therapeutics-Dirk Brockstedt, PhD, Chief Scientific Officer: CCR4 oncology program update
- Tempest Therapeutics-Dara L. Burdette, PhD, Executive Director: Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
- Eureka Therapeutics-Cheng Liu, PhD, Founder, President and CEO: Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)
Morning Sessions:
|
Time (PT)
|
Topic
|
|
8:45-9:00 am
|
PBSS Welcome and Symposium Overview, Shichang Miao (PBSS)
|
|
9:00-9:35 am
|
1. Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells
Kelsey Gauthier, PhD, Director of Biology, Arcus Biosciences
|
|
9:35-10:10 am
|
2. Developing Genetically-Validated Drugs Using 23andMe’s Genetic Database
Jennifer Low, MD, PhD, Head of Therapeutics Development, 23andMe
|
|
10:10-10:45 am
|
3. Challenging Cancer With Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor
Allison Roberts, PhD, Senior Scientist, Chemical Biology, Frontier Medicines
|
|
10:45-10:55 am
|
Major Sponsor’s Presentation (Fortrea CRO)
|
|
10:55-11:15 am
|
Break Period & Vendor Show
|
|
11:15-11:50 am
|
4. First-in-Class Covalent MENIN Inhibitors for AML
Alex Cacovean, MD, VP, Clinical Development, Biomea Fusion
|
|
11:50-12:25 pm
|
5. New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
Eric Blouin, SVP Oncology, Ipsos Healthcare
|
|
12:25-1:15 pm
|
Lunch
|
Afternoon Sessions:
|
Time (PT)
|
Topic
|
|
1:15-1:50 pm
|
6. ASCO Highlights
Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director, Evercore ISI
|
|
1:50-2:25 pm
|
7. Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity
Shiva Bhowmik, PhD, Founder & COO, Trio Pharmaceuticals
|
|
2:25-3:00 pm
|
8. Advancing Novel Modalities for the Treatment of Hematologic Cancers
Amar Patel, MD, Senior Director, Early Clinical Development, Bristol Myers Squibb
|
|
3:00-3:20 pm
|
Break
|
|
3:20-3:55 pm
|
9. Updates on CCR4 Antagonists for Oncology
Dirk Brockstedt, PhD, Chief Scientific Officer, RAPT Therapeutics
|
|
3:55-4:30 pm
|
10. Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
Dara L. Burdette, PhD, Executive Director, Tempest Therapeutics
|
|
4:30-5:05 pm
|
11. Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)
Cheng Liu, PhD, Founder, President and CEO, Eureka Therapeutics
|
|
5:05-5:35 pm
|
Panel Discussion (All Speakers)
|
|
5:35-6:30 pm
|
Happy Hour (sponsored by Alturas Analytics)
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|